Phase 12 Study to Test Safety and Effectiveness of AB-3028 Treatment in Men with Metastatic Castration-Resistant Prostate Cancer

What this Trial Is About

Researchers are evaluating AB-3028, a programmable circuit T cell therapy, in people with metastatic castration-resistant prostate cancer mCRPC whose disease has progressed after treatment with androgen receptor pathway inhibitors. This multi-center, open-label Phase 12 trial aims to assess the safety, tolerability, and efficacy of AB-3028. The treatment involves modifying the patients own T cells to recognize specific proteins found on prostate cancer cells, potentially enabling the immune system to target the cancer while avoiding damage to healthy tissues. Participants receive a single intravenous infusion of AB-3028 cells on day 0. In Phase 1, the study focuses on evaluating safety and determining the maximum tolerated or recommended dose. Phase 2 investigates the treatments effectiveness. After treatment, subjects enter a follow-up period during which safety, tolerability, and response to therapy are regularly monitored. Throughout the trial, participants undergo serial assessments to track safety and treatment effects for up to 24 months after infusion. These evaluations help researchers understand how well the therapy is tolerated and its impact on cancer. The study is designed to gain new knowledge that may benefit future patients with mCRPC.

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)